VRTX:NSD-Vertex Pharmaceuticals Incorporated (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 199.59

Change

-0.46 (-0.23)%

Market Cap

USD 51.84B

Volume

2.53M

Avg Analyst Target

USD 248.67 (+24.59%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+32.54 (+8.42%)

USD155.19B 259.06 194.72
BNTX BioNTech SE

+62.63 (+17.80%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

-5.56 (-0.95%)

USD62.49B 16.70 12.83
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

+1.64 (+0.48%)

USD31.54B N/A N/A
GMAB Genmab A/S

+0.11 (+0.24%)

USD29.62B 33.28 3.77
SGEN Seagen Inc

+5.02 (+3.17%)

USD28.78B 49.36 38.34
RPRX Royalty Pharma plc

-0.94 (-2.49%)

USD22.88B 31.06 13.91
ALNY Alnylam Pharmaceuticals, Inc

+4.63 (+2.59%)

USD21.02B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing VRTX

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+5.86 (+2.77%)

USD0.57B
PYF-B:CA Purpose Fund Corp. - Purp.. 0.00 % 0.73 %

N/A

N/A
SXR0:XETRA iShares VI Public Limited.. 0.00 % 0.35 %

N/A

USD0.10B
SMRN:XETRA Amundi Etf Istoxx Europe .. 0.00 % 0.00 %

-0.08 (-0.36%)

USD0.06B
IQQ0:XETRA iShares Edge MSCI World M.. 0.00 % 0.30 %

+0.04 (+0.08%)

USD3.35B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.21 (+3.36%)

USD0.40B
IQQ0:F iShares VI Public Limited.. 0.00 % 0.30 %

+0.15 (+0.30%)

USD3.35B
MKTN:PA Amundi ETF iStoxx Europe .. 0.00 % 0.00 %

-0.07 (-0.34%)

USD0.06B
VMOM:LSE Vanguard Global Momentum .. 0.00 % 0.00 %

N/A

USD0.07B
MVOL:LSE iShares VI Public Limited.. 0.00 % 0.30 %

-0.06 (-0.10%)

USD3.35B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.24 (+3.24%)

USD0.04B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

+0.17 (+3.19%)

USD0.48B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.24 (+3.28%)

USD0.48B
PYF-U:CA Purpose Fund Corp. - Purp.. 0.00 % 0.72 %

N/A

N/A
SPGP Invesco S&P 500 GARP ETF 0.00 % 0.34 %

-0.16 (-0.18%)

USD0.55B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+2.88 (+2.83%)

USD0.27B
HWF:CA Middlefield Healthcare & .. 0.00 % 1.45 %

N/A

USD0.05B
BUL Pacer US Cash Cows Growth.. 0.00 % 0.60 %

+0.15 (+0.38%)

USD3.81M
LS:CA Middlefield Healthcare & .. 0.00 % 1.31 %

+0.08 (+0.68%)

USD0.09B
QGRO American Century U.S. Qua.. 0.00 % 0.29 %

+0.47 (+0.64%)

USD0.27B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
VLQ:CA Vanguard Global Liquidity.. 0.00 % 0.37 %

N/A

USD0.01B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
PYF:CA Purpose Premium Yield Fun.. 0.00 % 0.73 %

-0.03 (-0.17%)

USD0.08B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

-0.05 (-0.21%)

USD0.06B
IBB iShares Biotechnology ETF 0.00 % 0.46 %

+2.75 (+1.62%)

USD10.82B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.45 (-2.58%)

USD9.12M
XDEB:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

+0.03 (+0.07%)

USD0.85B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.55% 48% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.55% 48% F 21% F
Trailing 12 Months  
Capital Gain -26.95% 40% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.95% 40% F 13% F
Trailing 5 Years  
Capital Gain 94.86% 73% C 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.86% 73% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 27.09% 60% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.09% 60% D- 73% C
Risk Return Profile  
Volatility (Standard Deviation) 32.39% 83% B 56% F
Risk Adjusted Return 83.64% 96% A 88% B+
Market Capitalization 51.84B 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 26.37 27% F 36% F
Price/Book Ratio 5.68 28% F 26% F
Price / Cash Flow Ratio 15.93 6% F 27% F
EV/EBITDA 17.81 26% F 47% F
Management Effectiveness  
Return on Equity 23.83% 96% A 90% A-
Return on Invested Capital 33.19% 94% A 95% A
Return on Assets 12.63% 97% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.60 73% C 65% D
Short Percent 1.58% 88% B+ 69% D+
Beta 0.66 81% B- 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.